Last updated: August 9, 2026
Quinapril hydrochloride/hydrochlorothiazide is an off-patent fixed-dose antihypertensive combination with limited branded competition and a technically manageable tablet-development pathway. The strongest commercial opportunity is a reliable, low-cost generic or authorized-generic product supported by moisture control, nitrosamine-risk management, rapid dissolution, and a differentiated excipient profile. The principal commercial constraint is market size: the combination competes with widely available ACE inhibitor/thiazide alternatives, including lisinopril/hydrochlorothiazide and losartan/hydrochlorothiazide.
What is quinapril hydrochloride and hydrochlorothiazide?
Quinapril hydrochloride/hydrochlorothiazide combines an angiotensin-converting enzyme inhibitor with a thiazide diuretic.
| Attribute |
Details |
| Active ingredients |
Quinapril hydrochloride and hydrochlorothiazide |
| Therapeutic class |
ACE inhibitor plus thiazide diuretic |
| Primary indication |
Hypertension |
| Historical U.S. brand |
Accuretic |
| Original sponsor |
Warner-Lambert/Parke-Davis; later Pfizer |
| FDA dosage strengths |
10 mg/12.5 mg, 20 mg/12.5 mg, and 20 mg/25 mg |
| Dosage form |
Immediate-release tablet |
| Administration |
Oral, once daily in labeled use |
| FDA pathway for new generic |
ANDA under section 505(j) |
| Biologic status |
Not applicable; biosimilar competition does not apply |
Quinapril is converted to quinaprilat, the pharmacologically active ACE inhibitor. Hydrochlorothiazide increases urinary sodium and fluid excretion. The combination can reduce blood pressure more effectively than either component alone in appropriate patients.
What excipients are used in quinapril hydrochloride/hydrochlorothiazide tablets?
Historical Accuretic labeling identifies a conventional tablet excipient system that includes magnesium carbonate, crospovidone, gelatin, magnesium stearate, povidone, talc, titanium dioxide, and iron oxides, with colorants varying by strength.[1]
A generic manufacturer does not need to reproduce the branded excipient composition. It must demonstrate pharmaceutical equivalence, bioequivalence, acceptable quality, and compliance with FDA inactive-ingredient requirements.
Historical excipient profile
| Excipient |
Likely function |
| Magnesium carbonate |
Alkalinizing agent, diluent, stabilizing aid |
| Crospovidone |
Superdisintegrant |
| Povidone |
Binder |
| Magnesium stearate |
Lubricant |
| Talc |
Glidant or anti-adherent |
| Titanium dioxide |
Opacifier |
| Iron oxides |
Tablet colorants |
| Gelatin |
Coating or capsule-related component in historical formulation |
The historical use of magnesium carbonate is technically relevant. Quinapril is susceptible to degradation, and an alkaline microenvironment can support stability. The excipient choice also affects dissolution, tablet hardness, powder flow, and moisture sensitivity.
What is the best excipient strategy for a generic product?
The preferred strategy is a low-moisture, immediate-release tablet platform using a controlled alkaline microenvironment, a robust disintegrant, and a low-risk lubricant system.
Recommended formulation architecture
| Formulation objective |
Preferred approach |
| Quinapril stability |
Alkaline buffering or microenvironmental pH control |
| Hydrochlorothiazide uniformity |
High-shear blending or granulation with validated segregation controls |
| Rapid disintegration |
Crospovidone or croscarmellose sodium |
| Powder flow |
Colloidal silicon dioxide or controlled granule sizing |
| Lubrication |
Magnesium stearate at the lowest effective concentration |
| Moisture protection |
Low-water processing and high-barrier packaging |
| Color differentiation |
Iron oxide-based film coating |
| Manufacturing simplicity |
Direct compression if content uniformity and flow are demonstrated |
| Scale-up robustness |
Dry granulation if direct compression is insufficient |
A direct-compression process can reduce manufacturing cost and eliminate water exposure. The main technical risks are the low-dose hydrochlorothiazide component, segregation between the two active ingredients, and variation in tablet tensile strength. Dry granulation can improve flow and content uniformity without introducing the moisture burden associated with aqueous wet granulation.
When is wet granulation appropriate?
Wet granulation is generally less attractive for this combination unless powder-flow or content-uniformity data require it. Water and elevated processing temperatures can increase the risk of quinapril degradation. If wet granulation is used, the process should employ a low-water or nonaqueous system with tightly controlled drying endpoints.
The formulation should be evaluated for:
- Quinapril hydrolysis and related substances
- N-nitroso-quinapril formation
- Hydrochlorothiazide degradation
- Dissolution after accelerated stability
- Tablet hardness and friability
- Blend and dosage-unit uniformity
- Sensitivity to humidity and oxygen
- Extractables and leachables from packaging
How does nitrosamine risk affect excipient selection?
Nitrosamine control is the central formulation and commercial issue for quinapril-containing products. FDA and manufacturers recalled certain quinapril and quinapril/hydrochlorothiazide products after detection or potential detection of N-nitroso-quinapril above acceptable intake limits.[2][3]
The risk is not limited to the active pharmaceutical ingredient. It can arise from the interaction of:
- A nitrosatable amine in quinapril
- Nitrite contamination in excipients
- Nitrosating species introduced through water or processing
- Heat, humidity, and prolonged storage
- Packaging-related migration or concentration effects
- Supplier changes involving excipient grade or manufacturing site
Excipient controls for nitrosamine mitigation
A sponsor should establish supplier-specific nitrite specifications for excipients rather than relying only on compendial compliance. Priority controls include:
- Testing excipients for nitrite and nitrate levels.
- Avoiding unnecessary use of nitrite-bearing or nitrogen-containing excipients.
- Qualifying multiple suppliers with comparable impurity profiles.
- Controlling water quality and process hold times.
- Monitoring the finished product for N-nitroso-quinapril throughout stability.
- Assessing the effect of alkaline excipients on both quinapril stability and nitrosamine formation.
- Using packaging with strong moisture and oxygen barriers.
Potentially useful formulation tools include low-nitrite grades of microcrystalline cellulose, mannitol, crospovidone, croscarmellose sodium, and colloidal silicon dioxide. Each excipient still requires supplier-specific analytical qualification.
The commercial value of a successful nitrosamine-control package is material. It can reduce recall risk, improve supply continuity, and support customer contracts with pharmacy chains, wholesalers, and government purchasers.
What formulations are protected by quinapril hydrochloride/hydrochlorothiazide patents?
The original product and combination patents are expired in the United States. Quinapril and the fixed-dose quinapril/hydrochlorothiazide product are mature small-molecule technologies, and no meaningful U.S. composition-of-matter exclusivity remains.
| Protection category |
Current commercial relevance |
| Quinapril composition patents |
Expired |
| Quinapril/hydrochlorothiazide combination patents |
Expired or commercially exhausted |
| Original tablet formulation patents |
Expired |
| Method-of-use patents |
Expired or not commercially blocking |
| Manufacturing patents |
Generally nonblocking for a standard generic process |
| Orange Book exclusivity |
No current new-drug exclusivity expected |
| Biosimilar exclusivity |
Not applicable |
The key intellectual-property exposure is therefore not an active branded patent estate. It is freedom to operate around manufacturing processes, impurity-control methods, analytical methods, and any newly developed formulation or packaging technology. A generic sponsor should still complete a current U.S. and international patent search before launch because private process patents, formulation applications, and jurisdiction-specific rights can differ.
What is the Orange Book status of Accuretic and generic quinapril/hydrochlorothiazide?
Accuretic was listed in the FDA Orange Book as a prescription product with quinapril hydrochloride and hydrochlorothiazide strengths. The product has been discontinued in the U.S. commercial market, and Pfizer announced recalls of certain lots in 2022 because of N-nitroso-quinapril concerns.[2][4]
The discontinued status of the reference product creates an important regulatory distinction:
- A discontinued reference product can remain the reference listed drug for ANDA purposes if FDA determines that it was not withdrawn for safety or effectiveness reasons.
- A sponsor must rely on FDA’s current reference-product and product-specific guidance position.
- The withdrawal and recall history increases the importance of impurity control and may affect FDA scrutiny of the proposed formulation.
- The ANDA must address the relevant labeling, strength, dosage form, and bioequivalence requirements.
The FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations remains the controlling source for current reference-product and therapeutic-equivalence information.[4]
When does quinapril hydrochloride/hydrochlorothiazide lose exclusivity?
The product lost meaningful U.S. exclusivity years ago. Original patent protection for quinapril and its combination with hydrochlorothiazide expired before the current generic market period. The remaining commercial issues are regulatory availability, supplier qualification, and product quality rather than patent expiry.
| Exclusivity type |
Status |
| New chemical entity exclusivity |
Expired |
| Pediatric exclusivity |
No current commercial barrier |
| Orphan exclusivity |
Not applicable |
| U.S. patent exclusivity |
Expired |
| Biosimilar exclusivity |
Not applicable |
| Generic exclusivity risk |
Potentially relevant only if a new ANDA applicant receives 180-day exclusivity |
A first-filer Paragraph IV applicant could theoretically obtain 180-day generic exclusivity if an unexpired listed patent were challenged. That scenario is unlikely to be commercially central for this mature combination, but FDA’s current listing controls the legal analysis.
Which companies are challenging or supplying quinapril hydrochloride/hydrochlorothiazide?
The product has historically been supplied by the brand sponsor and generic manufacturers. Generic availability has been constrained by market withdrawal and nitrosamine-related supply disruption rather than by an active patent dispute.
Relevant competitive groups include:
- Generic finished-dose manufacturers
- Contract development and manufacturing organizations
- API manufacturers supplying quinapril hydrochloride and hydrochlorothiazide
- Specialty suppliers with validated low-nitrite excipient systems
- Companies offering high-barrier blister or bottle packaging
A new entrant would compete primarily on:
- FDA approval status
- Reliable supply
- Low complaint and recall rates
- Nitrosamine testing capability
- Wholesale acquisition cost
- National wholesaler access
- Ability to offer all three strengths
- Packaging and serialization performance
What generic launch risks exist for quinapril hydrochloride/hydrochlorothiazide?
Regulatory risk
The ANDA must demonstrate bioequivalence to the reference product and meet current FDA expectations for nitrosamine risk assessment. The recall history means that a technically equivalent formulation with weak impurity controls would face avoidable approval and postapproval risk.
Manufacturing risk
Quinapril stability can be affected by moisture, pH, heat, and excipient variability. The manufacturing process should be designed around short exposure times, controlled humidity, and validated blend uniformity.
Market risk
The combination has a declining clinical profile relative to newer antihypertensive regimens. Physicians can prescribe generic lisinopril/hydrochlorothiazide, losartan/hydrochlorothiazide, valsartan/hydrochlorothiazide, or separate component products. This limits pricing power.
Commercial risk
A product may obtain approval but generate modest revenue because:
- The brand has lost promotional support.
- Prescribers have many substitutes.
- Pharmacy buyers prioritize price and supply reliability.
- The affected patient population is mature and treatment patterns are stable.
- Multiple generic strengths increase packaging and inventory complexity.
What commercial opportunities exist for a reformulated product?
The strongest opportunities involve operational differentiation rather than therapeutic innovation.
Low-nitrosamine generic
A manufacturer can position the product around robust N-nitroso-quinapril control, provided the claim is supported by validated data and complies with FDA communications and labeling rules.
Excipient-reduced formulation
A formulation using fewer excipients can support:
- Lower tablet mass
- Better patient acceptability
- Simpler global registration
- Reduced allergen and intolerance concerns
- Lower raw-material complexity
Any change must preserve bioequivalence, dissolution, stability, and content uniformity.
High-barrier packaging
Alu-Alu blister packaging or high-barrier bottles with desiccant can improve protection against humidity. Packaging differentiation is particularly relevant if the product is distributed in hot and humid markets.
Emerging-market supply
Markets with persistent demand for low-cost fixed-dose antihypertensives may offer better volume potential than the U.S. However, registration requirements, local patent status, pharmacopoeial standards, and reimbursement pricing vary by country.
Hospital and government tenders
The combination can fit institutional tenders where buyers value:
- Three approved strengths
- Consistent annual supply
- Competitive unit pricing
- Documented impurity controls
- Dual-source API and excipient procurement
How strong is the patent estate for quinapril hydrochloride/hydrochlorothiazide?
The patent estate is weak as a barrier to generic entry. The commercial moat is based on execution.
| Factor |
Assessment |
| Composition-of-matter protection |
No meaningful U.S. barrier |
| Combination protection |
Expired |
| Formulation protection |
Historical rights are expired |
| Method-of-use protection |
No material current barrier expected |
| Manufacturing complexity |
Moderate |
| Nitrosamine-control burden |
High relative to the product’s age |
| Bioequivalence complexity |
Moderate |
| Pricing power |
Low |
| Supply-chain opportunity |
Moderate |
| U.S. market attractiveness |
Limited to moderate |
The most defensible new intellectual property would likely relate to a validated low-nitrosamine formulation, specialized packaging, impurity-reduction process, or manufacturing control strategy. Such rights would need to satisfy novelty and non-obviousness requirements and would not automatically prevent competing generic products.
How does quinapril hydrochloride/hydrochlorothiazide compare with competing combinations?
| Product |
Main differentiation |
Commercial implication |
| Quinapril/HCTZ |
ACE inhibitor plus thiazide; mature product |
Limited growth, but possible supply-replacement opportunity |
| Lisinopril/HCTZ |
Widely prescribed ACE inhibitor combination |
Stronger generic demand and broader prescriber familiarity |
| Enalapril/HCTZ |
Older ACE inhibitor combination |
Similar low-cost positioning |
| Losartan/HCTZ |
ARB plus thiazide |
Often preferred where cough risk affects ACE inhibitor use |
| Valsartan/HCTZ |
ARB plus thiazide |
Established generic alternative |
| Amlodipine/benazepril |
Calcium-channel blocker plus ACE inhibitor |
Different mechanism and patient segment |
Quinapril/hydrochlorothiazide can remain clinically useful, but its commercial position is weaker than that of combinations with higher prescribing volume or fewer supply interruptions.
What licensing deals and partnerships are commercially relevant?
No active licensing transaction is required to commercialize a standard U.S. generic if the sponsor owns or contracts the ANDA, has API supply, and controls manufacturing. Practical partnership opportunities include:
- API supply agreements with dual qualified manufacturers
- CDMO arrangements for direct compression or dry granulation
- Excipient supplier agreements with nitrite specifications
- Contract packaging using high-barrier systems
- Regional licensing for markets where the combination remains actively prescribed
- Authorized-generic arrangements if a reference-product owner elects to reenter the market
The most valuable partnership is likely a combined API, finished-dose, and analytical-control package that reduces supply interruption risk.
Key Takeaways
- Quinapril hydrochloride/hydrochlorothiazide is an off-patent, immediate-release fixed-dose antihypertensive combination.
- The principal technical issue is N-nitroso-quinapril control, not patent exclusivity.
- A low-moisture process with alkaline stability control, strong disintegration, and high-barrier packaging is the preferred development direction.
- Direct compression is attractive if content uniformity and powder flow are demonstrated; dry granulation is a practical fallback.
- The U.S. commercial opportunity is based on supply reliability and quality differentiation rather than premium pricing.
- Biosimilar competition is irrelevant because both active ingredients are small molecules.
- The most promising markets are generic supply replacement, government tenders, and regions where fixed-dose ACE inhibitor/thiazide products remain established.
- Current FDA Orange Book and reference-product records should control the final ANDA and Paragraph IV analysis.
FAQs
Is quinapril hydrochloride/hydrochlorothiazide still commercially available?
The historical Accuretic brand was discontinued in the U.S., and certain products were recalled because of N-nitroso-quinapril concerns. Generic availability depends on current FDA-listed suppliers and market status.
Which excipient is most important for quinapril stability?
An alkaline excipient or buffering system can be important for quinapril stability, but the selected system must be evaluated together with nitrosamine formation, dissolution, and long-term degradation.
Can a generic manufacturer replace magnesium carbonate?
Yes. A generic formulation does not need to duplicate the branded excipient composition. The replacement must support stability, dissolution, bioequivalence, manufacturability, and regulatory acceptability.
Is quinapril hydrochloride/hydrochlorothiazide subject to biosimilar competition?
No. Quinapril and hydrochlorothiazide are small-molecule active ingredients regulated through the generic-drug pathway, not the biosimilar pathway.
What is the highest-value formulation innovation for this product?
A validated low-nitrosamine formulation combined with moisture-protective packaging offers the clearest commercial value. It addresses the principal historical supply problem while supporting reliable generic manufacture.
References
-
Pfizer Inc. (2019). Accuretic (quinapril hydrochloride and hydrochlorothiazide) tablets: Prescribing information. U.S. Food and Drug Administration labeling archive.
-
U.S. Food and Drug Administration. (2022). Pfizer voluntarily recalls five lots of Accuretic tablets and authorized generic quinapril hydrochloride/hydrochlorothiazide tablets due to the presence of a nitrosamine impurity. FDA Drug Safety Communication.
-
U.S. Food and Drug Administration. (2023). Control of nitrosamine impurities in human drugs: Guidance for industry. U.S. Department of Health and Human Services.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.
